Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig plus pumitamig with carboplatin and etoposide in extensive-stage small cell lung carcinoma
2026-525459-99-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of obrixtamig and pumitamig in small cell lung cancer (SCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events leading to discontinuation or dose modification. Planned start Oct 2026; status: authorised.
02
Drugs
obrixtamigpumitamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2026-525459-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525459-99-00.